Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19079771 | PROTEIN-ENCLOSING POLYMERIC MICELLE | March 2025 | February 2026 | Allow | 11 | 1 | 0 | No | No |
| 19067426 | SELF-ASSEMBLING NANOPARTICLES | February 2025 | January 2026 | Allow | 11 | 1 | 1 | Yes | No |
| 19062335 | MULTI-DOSE PEN OF TIRZEPATIDE | February 2025 | December 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 19041480 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | January 2025 | August 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18979068 | METHODS FOR TREATING ALZHEIMER'S DISEASE USING SEMAGLUTIDE | December 2024 | September 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18967259 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | December 2024 | June 2025 | Allow | 7 | 2 | 1 | No | No |
| 18870747 | HYDROLYZED COLLAGEN FOR USE IN REDUCING BLOOD GLUCOSE | December 2024 | January 2026 | Allow | 13 | 1 | 1 | Yes | No |
| 18929081 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | October 2024 | September 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18907424 | VASOPRESSIN PREMIX SYSTEMS AND USES THEREOF | October 2024 | July 2025 | Allow | 10 | 1 | 1 | No | No |
| 18889097 | Insulin Derivative | September 2024 | October 2025 | Abandon | 13 | 1 | 1 | Yes | No |
| 18807825 | APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18720291 | IL-4 DERIVED PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | June 2024 | April 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18634496 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | April 2024 | August 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18628440 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18444463 | COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF GLUCAGON-LIKE PEPTIDE-1 ANALOGS AND USES THEREOF | February 2024 | December 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18573779 | METHODS OF USING AND COMPOSITIONS INCLUDING AN INCRETIN ANALOG | December 2023 | August 2025 | Allow | 20 | 1 | 0 | No | No |
| 18572577 | SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOF | December 2023 | October 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18510553 | ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR | November 2023 | December 2025 | Allow | 25 | 1 | 1 | No | No |
| 18499523 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | November 2023 | October 2025 | Allow | 23 | 1 | 0 | No | No |
| 18384511 | PRODRUGS AND USES THEREOF | October 2023 | February 2026 | Abandon | 27 | 1 | 1 | No | No |
| 18477276 | Compositions and Methods for Peptide Production | September 2023 | November 2025 | Allow | 26 | 1 | 0 | No | No |
| 18449876 | BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS | August 2023 | September 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18230086 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | August 2023 | July 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18357666 | TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES | July 2023 | November 2025 | Allow | 28 | 1 | 0 | No | No |
| 18354452 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | July 2023 | January 2026 | Allow | 30 | 2 | 0 | No | No |
| 18221206 | SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOF | July 2023 | October 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18345775 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | June 2023 | March 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18345832 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | June 2023 | July 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18341404 | METHOD OF REDUCING GLUCOSE INTOLERANCE OR INSULIN RESISTANCE IN A PATIENT IN NEED THEREOF | June 2023 | June 2025 | Allow | 24 | 1 | 0 | No | No |
| 18331197 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | June 2023 | April 2025 | Allow | 22 | 2 | 1 | No | No |
| 18331318 | Lyophilized Formulation | June 2023 | April 2024 | Allow | 10 | 1 | 1 | No | No |
| 18206963 | STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF | June 2023 | January 2026 | Allow | 32 | 1 | 1 | No | No |
| 18329358 | METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | June 2023 | January 2026 | Allow | 31 | 1 | 1 | No | No |
| 18199817 | GATA3 INHIBITORS FOR TREATING INSULIN RESISTANCE | May 2023 | June 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 18319010 | Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug | May 2023 | July 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18318492 | METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX | May 2023 | March 2025 | Allow | 22 | 1 | 0 | No | No |
| 18196813 | PREPARATION COMPRISING EXANATIDE FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT | May 2023 | June 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18304074 | NOVEL METHOD FOR PREPARING LONG-ACTING DRUG CONJUGATE THROUGH PREPARATION OF INTERMEDIATE | April 2023 | August 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18136236 | METHOD OF DELIVERING GONADOTROPIN RELEASING HORMONE OR AN ANALOGUE THEREOF INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | April 2023 | April 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18300354 | METHODS OF REDUCING NEUROINFLAMMATION | April 2023 | January 2026 | Allow | 34 | 1 | 0 | No | No |
| 18028747 | CLEC2 FUSION PROTEIN AND USES THEREOF | March 2023 | February 2026 | Allow | 35 | 1 | 0 | Yes | No |
| 18122991 | RECONSTITUTABLE TEVERELIX-TFA COMPOSITION | March 2023 | July 2025 | Allow | 28 | 2 | 1 | No | No |
| 18186098 | APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF | March 2023 | October 2025 | Allow | 31 | 1 | 1 | No | No |
| 18181852 | NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX | March 2023 | February 2025 | Allow | 23 | 1 | 0 | No | No |
| 18021712 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | February 2023 | February 2026 | Allow | 36 | 1 | 1 | No | No |
| 18087345 | ADMINISTRATION OF AN ANTI-ACTIVIN-A COMPOUND TO A SUBJECT | December 2022 | April 2025 | Allow | 28 | 1 | 0 | No | No |
| 18087273 | SHORT CHAIN CERAMIDE-BASED LIPIDS AND USES THEREOF | December 2022 | April 2025 | Allow | 28 | 1 | 0 | No | No |
| 18077742 | USE OF ULTRARAPID ACTING INSULIN | December 2022 | February 2025 | Allow | 27 | 1 | 0 | No | No |
| 18061182 | FIBROBLAST GROWTH FACTOR 1 (FGF1) MUTANT PROTEINS THAT SELECTIVELY ACTIVATE FGFR1B TO REDUCE BLOOD GLUCOSE | December 2022 | March 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17927304 | DUAL-AGONIST COMPOUND FOR BOTH GLP-1 AND GIP RECEPTORS AND APPLICATION THEREOF | November 2022 | December 2025 | Allow | 37 | 1 | 0 | No | No |
| 17988271 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | November 2022 | February 2026 | Allow | 39 | 2 | 1 | No | No |
| 17997363 | Treating Cancer with a Conjugate Comprising an IL-2 Moiety | October 2022 | May 2025 | Allow | 31 | 1 | 1 | No | No |
| 18049445 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION | October 2022 | March 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17930144 | USE OF GP73 INHIBITOR IN PREPARATION OF MEDICINE FOR TREATING DIABETES | September 2022 | March 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17929209 | Targeting gamma-delta T Cells in Obesity and Cachexia | September 2022 | March 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17895638 | INSULIN-TRANSFERRIN FUSION PROTEIN AND ITS PRODRUG, PROINSULIN-TRANSFERRIN, FOR OVERCOMING INSULIN RESISTANCE | August 2022 | April 2025 | Allow | 32 | 2 | 0 | No | No |
| 17869948 | METHODS FOR PROGNOSING AND PREVENTING METASTATIC LIVER DISEASE | July 2022 | April 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17813383 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DIABETES AND RELATED DISORDERS | July 2022 | November 2024 | Allow | 28 | 1 | 0 | No | No |
| 17863322 | METHODS FOR DELIVERING ETANERCEPT PREPARATIONS INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17758089 | Insulin Derivative | June 2022 | November 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17848974 | COMPOSITIONS AND METHODS FOR TREATING OBESITY AND HYPERPHAGIA | June 2022 | October 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17785786 | IL2 MUTEINS | June 2022 | December 2025 | Allow | 42 | 1 | 1 | No | No |
| 17836644 | ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF | June 2022 | December 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17836707 | ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF | June 2022 | January 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 17781530 | Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma | June 2022 | March 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17747723 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1-AGONIST AND METHIONINE | May 2022 | January 2025 | Allow | 32 | 1 | 0 | No | No |
| 17741126 | Long-Acting Therapeutic Fusion Proteins | May 2022 | March 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17724406 | BIOMARKERS OF FAST PROGRESSION OF CHRONIC KIDNEY DISEASE | April 2022 | September 2024 | Allow | 29 | 0 | 1 | No | No |
| 17721112 | METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY | April 2022 | March 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17695343 | PHARMACEUTICAL COMBINATION FOR IMPROVING GLYCEMIC CONTROL AS ADD-ON THERAPY TO BASAL INSULIN | March 2022 | March 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17692238 | INSULIN CONTAINING PHARMACEUTICAL COMPOSITIONS | March 2022 | November 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17634685 | INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS | February 2022 | December 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17667223 | A METHOD FOR TREATING DIABETES | February 2022 | November 2024 | Allow | 34 | 2 | 1 | No | No |
| 17588377 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION | January 2022 | January 2025 | Allow | 36 | 1 | 0 | No | No |
| 17586872 | Methods of Treatment Using G-CSF Protein Complex | January 2022 | September 2024 | Allow | 31 | 1 | 0 | No | No |
| 17562435 | RAPID-ACTING INSULIN ANALOGUES OF ENHANCED STABILITY | December 2021 | January 2025 | Allow | 37 | 1 | 0 | No | No |
| 17549770 | PHARMACEUTICAL COMPOSITION COMPRISING FRATAXIN FUSION PROTEIN AND METHODS OF USE THEREOF | December 2021 | April 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17615595 | HLA TUMOR ANTIGEN PEPTIDES OF CLASS I AND II FOR TREATING MAMMARY/BREAST CARCINOMAS | December 2021 | November 2025 | Allow | 54 | 1 | 1 | Yes | No |
| 17534291 | METHODS OF INCREASING PROGRANULIN LEVELS USING ANTI-SORTILIN ANTIBODIES | November 2021 | February 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17534270 | METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY | November 2021 | January 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17611478 | FORMULATIONS OF TERLIPRESSIN | November 2021 | September 2024 | Allow | 34 | 1 | 0 | No | No |
| 17519305 | ACTRIIB LIGAND TRAP COMPOSITIONS AND USES THEREOF | November 2021 | August 2024 | Allow | 34 | 2 | 1 | No | No |
| 17507441 | STEM CELL RICH PLASMA COMPOSITIONS AND USES THEREOF FOR TREATING AGING SUBJECTS | October 2021 | September 2024 | Allow | 35 | 1 | 1 | No | No |
| 17499296 | Method and Compounds for Treating Diabetes and Associated Metabolic Diseases | October 2021 | September 2024 | Allow | 35 | 5 | 1 | Yes | No |
| 17461748 | PHOTORESPONSIVE LIPOSOME, COMPLEX, MEASUREMENT SYSTEM, AND MEASUREMENT METHOD | August 2021 | August 2025 | Allow | 48 | 1 | 1 | No | No |
| 17443737 | METHOD FOR SCREENING OF UNPLEASANT ODOR MASKING AGENTS | July 2021 | December 2024 | Allow | 40 | 1 | 0 | No | No |
| 17378184 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC HEART DISEASE | July 2021 | February 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17332578 | NUCLEIC ACID MOLECULES ENCODING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | May 2021 | August 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17327498 | GLUCOSE RESPONSIVE INSULINS | May 2021 | September 2024 | Allow | 40 | 2 | 1 | No | No |
| 17320118 | ENGINEERED CD25 POLYPEPTIDES AND USES THEREOF | May 2021 | June 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17292701 | COMBINATION THERAPIES FOR MULTIPLE MYELOMA | May 2021 | March 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17315168 | APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF | May 2021 | January 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17289898 | Combination Therapy Method of Treating Myeloproliferative Neoplasms with a Diphtheria Toxin-Human Interleukin-3 Conjugate in Combination with Other Agents | April 2021 | March 2025 | Allow | 47 | 1 | 1 | No | No |
| 17237650 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | April 2021 | August 2023 | Allow | 27 | 3 | 0 | No | No |
| 17286445 | SPHINGOSINE KINASE 1 AND FUSION PROTEIN COMPRISING THE SAME AND USE THEREOF | April 2021 | December 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17224068 | LYOPHILIZED MESENCHYMAL STEM CELL DERIVED SECRETOME AND USES THEREOF | April 2021 | August 2024 | Allow | 41 | 2 | 1 | No | No |
| 17151045 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | January 2021 | March 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17256326 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | December 2020 | November 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 17254004 | NOVEL INTERLEUKIN-15 (IL-15) FUSION PROTEINS AND USES THEREOF | December 2020 | February 2025 | Allow | 50 | 1 | 1 | No | No |
| 17118915 | METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS | December 2020 | April 2025 | Allow | 52 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANDRA, GYAN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHANDRA, GYAN works in Art Unit 1674 and has examined 281 patent applications in our dataset. With an allowance rate of 96.8%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner CHANDRA, GYAN's allowance rate of 96.8% places them in the 87% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHANDRA, GYAN receive 1.88 office actions before reaching final disposition. This places the examiner in the 45% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CHANDRA, GYAN is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +3.0% benefit to allowance rate for applications examined by CHANDRA, GYAN. This interview benefit is in the 24% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 34.9% of applications are subsequently allowed. This success rate is in the 78% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 58.1% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 78.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 39.5% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 39.5% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.